SUNA and AUA Revise Joint Statement on Intravesical Administration of Therapeutic Medication for Bladder Cancer Treatment

SUNA and the American Urological Association (AUA) recently updated their joint statement on Intravesical Administration of Therapeutic Medication for the Treatment of Bladder Cancer. The purpose of the statement is to define the performance guidelines surrounding the instillation of intravesical cytotoxic, immunotherapeutic, and/or therapeutic drugs via sterile technique catheterization for patients with non-muscle invasive bladder cancer (NMIBD, urothelial carcinoma).

Originally developed in July 2015, the paper was reviewed and revised in June 2020. Members of the 2020 workgroup included Roxy Baumgartner, RN, APN-BC; Sam Chang, MD; Susan Flick, CNP; Howard Goldman, MD, FACS; Jim Kovarik, MS, PA-C; Yair Lotan, MD; Elspeth McDougall, MD, FRCSC, MHPE; Arthur Sagalowsky, MD; Edouard Trabulsi, MD; Debbie Hensley, RN; Christy Krieg, MSN, CUNP; and Leanne Schimke, MSN, CUNP.

Download the Statement